



Co-funded by
the European Union

EU4H-2023-JA-3-IBA - Joint Action JANE-2 - GA 101183265



Joint Action on Networks of Expertise on Cancer

Milestone number. 10.1

1st Hi-tech NoE Annual activity report

30 November 2025

Co-funded by the European Union. Views and opinions expressed are, however, those of the author(s) only and do not necessarily reflect those of the European Union or HaDEA. Neither the European Union nor the granting authority can be held responsible for them



DOCUMENT INFORMATION

Author(s):	Venice Hancock, Jean-Yves Blay
Milestone lead partner:	Unicancer (FR) and ZEALCO (DK)
Contributing partner(s):	Region Zealand, National and Kapodistrian University of Athens, Hospital Universitario y Politécnico La Fe, CONSELLERIA DE SANIDAD – GENERALITAT VALENCIANA, National Hellenic Research Foundation, Centro Nazionale di Adroterapia Oncologica (CNAO), Oslo University Hospital, Department of Oncology (OUS), Institute of Oncology Ljubljana, Istituto Romagnolo per lo Studio dei Tumori Dino Amadori



TABLE OF CONTENTS

1	Executive summary	4
2	Introduction.....	5
3	Tasks 10.1 - Governance of the NoE	6
4	Task 10.2 – Advocacy: Establishing recommendations for Member States regarding urgent needs and biggest gaps across Europe	8
5	Task 10.3 - Innovation Observatory - Positioning the network at the forefront of innovation.....	10
6	Task 10.4 - Infrastructural and procedural support.....	11
7	Task 10.5- Education and Training.....	12
8	Task 10.6 – Dissemination and sustainability	13
9	Governance of the NoE	14
10	Dissemination activities.....	15
	Dissemination activities from individual domains.....	15
11	Synergies with the NoE.....	18
12	Collaborating stakeholders of the NoE.....	19
13	Sustainability.....	21



1 EXECUTIVE SUMMARY

This report goes over the key achievements and activities carried out by WP10 during the first year of the JANE 2 Joint Action (M1-12). It details all activities led by each of its seven specialized domains (Nuclear Medicine; Radiomics; Innovative Radiotherapy; Innovative surgery; Physical Methods of Ablation; Cell Therapies and Ex Vivo Testing of Agents).

The report includes descriptions of the organization of the work of the NoE through various meetings (in person and online), along with the organization of each of the seven domains and what activities have been carried out by the entire network throughout the first year of the joint action.

It goes over task activities, dissemination activities, governance of the NoE, partner contributions, collaborating stakeholders, collaboration and synergies and sustainability.



2 INTRODUCTION

The objectives of the NoE on Hi-Tech Medical Resources are to establish a robust governance structure and provide strategic recommendations to Member States on urgent needs and key gaps related to innovative therapies across Europe. The NoE aims to position itself at the forefront of innovation by supporting centres in integrating cutting-edge therapies and enhancing the continuous education of healthcare professionals, while also improving patient and public literacy and engagement. To achieve this, the NoE is divided into seven highly specialised high-tech domains (nuclear medicine, radiomics, innovative radiotherapy, innovative surgery, physical methods of ablation, cell therapies and ex-vivo testing of agents) with a diverse and wide set of experts engaged from across Europe. Ensuring the visibility and sustainability of the network is a core focus, achieved through targeted dissemination activities and the development of information tools. The NoE seeks to engage both international and national scientific societies (e.g., ESMO, ESTRO) and relevant stakeholders, as well as EU bodies such as the EMA and EUnetHTA, to help identify and overcome barriers to implementation. Collaboration with patient advocacy groups is also a key component, ensuring that the network remains inclusive, useful and patient-centred.



3 TASKS 10.1 - GOVERNANCE OF THE NOE

- **Achievements**

Governance model successfully delivered (D10.1). Establishment of clear, sustainable and precise governance model for the general NoE Hi-Tech Medical Resources, as well as for each of the seven domains within the NoE. Working together as a network to bring this together to give the NoE a proper structure.

The paper provides a detailed overview of the construction of 8 sustainable, efficient and easy to implement models.

- **Challenges encountered**

While the governance model was successfully delivered on time, it was a complex undertaking, challenging many experts who had to expand their scope of knowledge to create and propose a relevant governance model. Emphasis on sustainability and longevity of these models meant that a great deal of work needed to be put into this task.

- **Deviations in activities and justifications**

There were no deviations to this work. The complete deliverable was submitted on time as expected.

- **Contribution of partners**

The full detail of contribution of partners is detailed at the end of the report. All WP10 partners were invited to provide feedback and comments on the governance work.

Each domain involved their partners directly when working on individual domain governance models, this was done through email discussions or domain meetings. At the WP10 level, this topic was raised during various WP10 online meetings, during which partners were invited to share feedback on the overall proposed governance structure.

- **Use of resources**

WP10 coordination actively worked on building a framework that could be applicable for the overall NoE structure, as well as a format all domains could work on. Domain leaders were in charge of putting together their own domain governance models, taking into consideration domain needs and specificities. The rest of WP10 contributors (complete partner list includes close to 250 participants) were also invited to provide feedback via WP10 online meetings, and via individual domain leaders.

- **Activities planned moving forward**



The D10.1 has been thought out to be implemented throughout project period and past the end of the joint action to ensure sustainability, this is a priority for domain leaders and WP10 coordinators.



4 TASK 10.2 – ADVOCACY: ESTABLISHING RECOMMENDATIONS FOR MEMBER STATES REGARDING URGENT NEEDS AND BIGGEST GAPS ACROSS EUROPE

- **Achievements**

All domains have begun working on paper on emerging uses of hi-tech innovation in described domains and implications and strategies for access across Europe. A key ambition of this compilation paper (D10.3) will be to cover challenges in healthcare inequity to help better implement and improve accessibility to innovative therapies & highlighting opportunities for more efficient & sustainable healthcare systems across Europe. Each of the seven domains will have a section of the paper about their own technology, and they are encouraged to develop a more in-depth paper dedicated to their domain.

Development of mapping and survey activities to better understand obstacles to health equality and accessibility for Hi-tech advances in Europe.

WP10 coordination is currently working on creating a framework for the development of this paper in order to present a coherent piece of writing.

- **Challenges encountered**

So far, while no challenges have been encountered regarding this task, this is a complex topic which requires a lot of effort which is why work has started sooner than anticipated. Many domains are working on including contributors who are keen on contributing. Work is advancing as planned.

- **Deviations in activities and justifications**

So far, there have been no deviations in activities. Although work on this task has begun as early as M1 of the project, ahead of M7 predicted in the grant agreement GANTT chart, as this is a key topic and added value provided by our NoE.

- **Contribution of partners**

Domain leaders and WP10 contributors have been made aware of this work by WP10 contribution, and are actively contributing to the construction of the work.

- **Use of resources**

Once the JANE 2 coordination makes the survey tool available, WP10 partners will be able to make use of it to conduct mapping and survey activities related to the needs of this task.



Ideally, we would receive a clear path on how to add more partners, as there has been much interest in the NoE, and how to change the contribution level of certain partners in order to reflect the work being done and facilitate the work of each of the seven domains.

In terms of methodology, this topic has been addressed in both general WP10 meetings (Kick-Off meeting, annual meeting and regular online meetings) and individual domain meetings (whether domain-wide, or dedicated domain meetings to this topic).

- **Activities planned moving forward**

WP10 coordination is working on finalising the framework of the paper, domain leaders are also contributing to this work as they will be authors alongside specialists from domains. This will be a key topic of discussion during the WP10 annual meeting on November 5th.

Each domain will be encouraged to begin working on mapping, surveying if there is a need, or to investigate useful existing resources before beginning organizing the work process and the drafting of their specific section of the compilation paper, as well as their individual in-depth papers.



5 TASK 10.3 - INNOVATION OBSERVATORY - POSITIONING THE NETWORK AT THE FOREFRONT OF INNOVATION

- **Achievements**

The building blocks for this task have been set, through cementing the need for identifying new therapies and evolutions in the Hi-tech domains in close collaboration with domain leaders in the proposed governance model described in D10.1 and initiating contact with patient organization to set up collaboration on questions of how innovation can be led through medicine and identifying collaboration with relevant stakeholders.

- **Challenges encountered**

So far, no challenges have been encountered regarding this task. Each of the seven domains are involved in this, therefore specific challenges will come up based on the particularities of the technologies addressed and solutions will vary from domain to domain. They are all focusing on innovation, as will be evidenced by papers produced.

- **Deviations in activities and justifications**

N/A.

- **Contribution of partners**

Partner contribution detailed in dedicated section.

- **Use of resources**

Work carried out by WP10 leadership and domain leadership teams to engage with external partners. Each domain is encouraged to interact with external stakeholders based on their specific needs, thinking about the particularities of each technology as a driver.

- **Activities planned moving forward**

Key activities in this task to carry the work through to the end of the joint action include: working on the elaboration of clinical guidelines for each of the seven domains with relevant stakeholders, continuing to collaborate with patient organisations to establish an action plan on how innovation should be led through medicine, actively working to identify challenges from bench to bedside transition and implementation.



6 TASK 10.4 - INFRASTRUCTURAL AND PROCEDURAL SUPPORT

- **Achievements**

Work on D10.3 has begun and will consider how to help centres, regions and countries better integrate Innovative therapies and have better access to Hi-Tech medical resources. D10.2 (patient information tool) will also be a key output in supporting centres.

Links with other Joint Actions, specifically EUNetCCC are being considered to support this work and prioritise collaborations.

- **Challenges encountered**

None so far.

- **Deviations in activities and justifications**

N/A.

- **Contribution of partners**

Work on developing paper framework is done by WP10 leadership, with input from domain leaders, before encouraging partner contribution in order to produce clear work.

- **Use of resources**

Development of D10.2 and D10.3 framework by WP10 leadership.

- **Activities planned moving forward**

Development of D10.3 and consideration on how to address the following issues: Facilitating the implementation of the adaptation of Clinical Practice Guidelines into standards of care; helping less advanced centres/countries; speeding up the road from innovation to patient benefit.



7 TASK 10.5- EDUCATION AND TRAINING

- **Achievements**

The NoE and individual domains have concentrated on establishing their activities and delivering key early outputs, including the completion of D10.1 (due at month 10) and the initiation of work on D10.2 and D10.3 which will be the next two key deliverables. Questions of education and training are key elements of this work, with domains already discussing this topic with a focus on the needs of their technology through input from highly specialized technical experts contributing to the domains.

Activities such as online webinars and working with Patient Organisations have already taken place, we are anticipating these to become more common and regular as the project goes on and the NoE becomes more established. The building blocks of this task are being set, making our NoE ready to engage effectively with it.

- **Challenges encountered**

So far, no challenges have been encountered regarding this task.

- **Deviations in activities and justifications**

N/A.

- **Contribution of partners**

Partner contribution detailed in dedicated section.

- **Use of resources**

Coordination and planning from WP10 leadership, including domain leadership.

- **Activities planned moving forward**

Continuing to envisage how to successfully construct training and education activities such as online workshops or webinars and capacity building activities.

Thinking about how to initiate active collaboration with EUNetCCC (WP5 and WP6) on capacity building activities and education and training criteria.



8 TASK 10.6 – DISSEMINATION AND SUSTAINABILITY

- **Achievements**

See dedicated section on dissemination activities for all WP10 domains, starting from page 14 of the report.

- **Challenges encountered**

Lack of shared platform provided by coordination team in first few months of project made discussions or sharing content with WP2 difficult, smoother since we have received access to TEAMS. There are still some ongoing issues (security related) which hinder certain partner's access to this platform. Lack of website in first months of project was also an issue when disseminating about JANE 2 WP10 activities to external collaborators.

- **Deviations in activities and justifications**

Work on this task has been carried out throughout the project period, from M1, ahead of M7 as described in the grant agreement GANTT chart.

- **Contribution of partners**

WP10 leadership has been key in terms of communicating with WP2 and properly coordinating the work between both WPs, domain leaders have been active in disseminating about WP10 to partners and external partners.

Individual partners have been disseminating about the project and their involvement in it through social media, specifically LinkedIn.

- **Use of resources**

Use of shared JANE 2 TEAMS platform and contribution to website.

- **Activities planned moving forward**

- Selecting at least 1 or 2 use cases (or pilot projects) and defining added value outcome (linked to D10.5) by end of Joint Action.
- Continued dissemination of project and WP10 activities at various levels (political, regional, national, professional, etc...).
- Dissemination about upcoming deliverables and production of papers.



9 GOVERNANCE OF THE NOE

The governance models have been established, both for the overall Hi-Tech Medical Resources NoE, as well as for each of the seven domains within the wider NoE. These were meticulously outlined in Deliverable 10.1: Recommendation paper for the for the future governance of the NoE on Hi-tech Medical Resources (Submitted by Unicancer on August 26th 2025).

The proposed governance structure of the NoE on Hi-Tech Medical Resources looked at establishing frameworks that are effective during the Joint Action, while also being sustainable beyond its conclusion. The deliverable noted that ensuring the NoE's long-term impact will require alignment not only with other NoEs of JANE2, but also with ongoing Joint Actions to promote broader European coordination and synergies.

The recommendation paper also detailed that maintaining the network's relevance will also depend on its ability to remain durable, adaptable, and responsive to technological developments and the evolving needs of patients and stakeholders across the EU. Early discussions have explored options for hosting the NoE secretariat within trusted organisations, potentially with rotating or renewable arrangements, to support its continuity past the end Joint Action period.

These reflections underscored an overall strong commitment to building a governance model that is credible, flexible, and sustainable over the long term.



10 DISSEMINATION ACTIVITIES

- Successful active dissemination of the NoE's mission and activities among relevant collaborators, consistent with the global sustainability strategy of the NoE, both by WP10 coordination, and domain leaders and co-leaders.
- WP10 coordination team (Unicancer project management) actively participates and contributes to WP2 through active attendance to their monthly meetings, contribution to the Newsletters by providing feedback and writing paragraphs about work undertaken in WP10, giving feedback the construction of the JANE 2 website. WP10 coordination team also made the recommendation to add dedicated tab for patients following discussion with domain leaders. This links directly to the ongoing work on D10.2 (deliverable on patient information tool).
- Successful organization of the WP10 Kick-off meeting in Copenhagen on November 28th and 29th 2024. Over 50 NoE participants attended in person, and almost 100 more participated online. External stakeholders were also a key part of the kick-off by participating in person.
- JANE 2 Kick-off meeting in Milan: WP10 made in active contribution to the JANE 2 kick-off meeting, with presentations from both NoE leaders, and all 7 domains.
- A “Newcomer’s workshop” was organized by WP10 coordination team, specifically for new members of the NoE on February 20th 2024, in order to welcome them to the network and help them understand the ambitions of JANE 2 and how they will contribute to the project.
- WP10 coordination team has been actively working on the WP10 annual meeting, taking place on November 5th 2025 in Paris. Domain leaders are all attending this meeting in person, and a hybrid session with the rest of the project partners is also being organized.
- In addition to collaborating with WP2, there is consistent direct communication on social media and LinkedIn. The WP10 coordination team has created social media posts about WP10 activities for the JANE 2 social media and website, along with personal posts being made by domain specialists on the project. This ensures continued visibility and impact for the NoE and JANE 2 as a whole.

Dissemination activities from individual domains

- **Domain 1:**
 - Members of the domain have been actively disseminating the challenges of the domain in several open-doors events, this was work carried out by the domain co-leaders:



-Dr. Stefan Prado and Dra. Irene Torres - 16/12/2024:

<https://www.iislafe.es/es/sociedad/eventos/514/jaima-2024-medicina-nuclear-imagen-molecular-y-lateragnostica>

-Dr. Stefan Prado - 03/03/2025: <https://www.oncobites.tv/news/rlt-talks-un-programa-sobre-los-radioligandos-en-primera-l%C3%ADnea-para-tumores-neuroendocrinos>

- **Domain 2:**

- Meeting and contacts were conducted with the following relevant persons in the fields: Luc Bidaut (IEEE and EORTC cross discipline Imaging Group); Andre Dekker (MAASTRO Clinic); Umberto Sabatini (Neuroradiologist University Magna Graecia of Catanzaro); Benjamin Lemasson (Grenoble Institut des Neurosciences); Stine Sofia Korreman (ESTRO Focus Group on AI in Radiotherapy)--> Plan to meet her in Toulouse (as she will attend the ESTRO Physics Workshop 2025).

- **Domain 3:**

- Presentation of the Innovative Radiotherapy Domain at the CAEN Conference (Caen, March 10 2025) – Symposium “From Proton to Heavy Ions Radiotherapy” focused on the intersection between clinical indications and technological innovation in radiotherapy.
- Presentation of the Innovative Radiotherapy Domain at the annual EPTN Conference (Prague, March 22 2025) – presentation focused on the preliminary work carried out so far, the work path ahead and the role of the OTGs.

- **Domain 4:**

- The Jane-2 project will be presented at the ESSO (European Society for Surgical Oncology) conference in Gothenburg 15-17 October 2025. Discussion of project activities with representatives of all national surgical oncology societies.

- **Domain 5:**

- The JANE-2 project was presented at the Slovenian Congress of Electroporation in Ljubljana on the 14th of March 2025. During the open seminar slot, the project was introduced to the public, sparking a broad discussion on the current state and future of physical ablation methods in Slovenia.
- Domain 5 prepared a leaflet to promote our domain between potential stakeholders.
- Zealand University Hospital presented the JANE-2 project at an event called “Cancer research at Zealand University Hospital from a European perspective” that took place on 26th of February 2025. Audience included Zealand regional council chairman and regional council director and other important stakeholders, including a member of the European Parliament, Marianne Vind.
- “Jane2 from a Danish perspective” was presented in March 2025 at a meeting organized by the Danish Comprehensive Cancer Centre (DCCC).

- **Domain 6:**

- Presentation of JANE-2 during a satellite session jointly organized by the GoCART Coalition and T2Evolve, immediately before the 7th EBMT-EHA EU CAR-T Cells Meeting that took place in Strasbourg, France, February 6-8, 2025.



- **Domain 7:**

- Contact with and presentation of JANE 2 and domain activities to key stakeholders: CROs and biotechs: Janvier Lab, CrowBiosciences. Also discussions with academic partners: PEPR MED-OoC "organ-on-chips" (Xavier Gidrol and Arnaud Millet au CEA Genoble).



11 SYNERGIES WITH THE NOE

- Active collaboration with WP9 (NoE Omics) to avoid overlap and identify key areas of collaboration where relevant.
- Meetings have taken place between WP9 (Omics) and Domain 7 of WP10 (Ex-Vivo Testing of Agents) and Domain 2 of WP10 (Radiomics) to ensure proper synergies, information sharing and collaboration.
- WP10 actively contributes to all WP2 activities by providing feedback, written contributions and general collaboration.
- WP10 also collaborates with WP3 on evaluation and setting up WP10 KPIs for the project duration.



12 COLLABORATING STAKEHOLDERS OF THE NOE

Stakeholders who made presentations during the WP10 Kick-off meeting about the relevance of JANE 2 and how we can successfully work with existing scientific societies:

- European Society of Medical Oncology (ESMO)
- European Society of Surgical Oncology (ESSO)
- European Association of Nuclear Medicine (EANM)
- European Society for Radiotherapy and Oncology (ESTRO)
- European Society for Blood and Marrow Transplantation (EBMT)
- Swedish Network Against Cancer

Each domain has also been encouraged to identify and begin working with relevant stakeholders for their domain work:

- **Domain 1:**
 - Since september 2025, Dra. I. Torres (domain co-leader) is involved in a working group organized by Novartis, which main goal is to work in radioligand therapy and in the regulatory issues to implement such technique within the clinical routine.
 - EANM.
- **Domain 2:**
 - LITO Institut Curie: Fanny Orlhac NCT/UCC: Alexander Zwanenburg - have been actively contributing and should be made high contributors, not observers. Further stakeholders will be engaged in coming year.
- **Domain 3:**
 - Two meetings were held with ESTRO representatives to explore possible collaboration areas, particularly regarding emerging radiotherapy technologies with promising yet still uncertain clinical benefit (hadron therapy, online adaptive radiotherapy, seated radiotherapy, artificial intelligence). The possibility to appraise and field-test these innovative technologies, in collaboration with other expertise across Europe, was discussed.
 - Two meetings were held with CERN researchers, focusing on innovation pathways — from novel technologies to market implementation. Discussions addressed the variability in clinical validation timelines, feasibility assessments, and cost-effectiveness between software-based innovations (e.g. fast dose calculations, deformable image registration) and hardware-based innovations (e.g. new planning and delivery systems). Particular emphasis



was placed on ensuring universal accessibility to innovative technologies (“democratisation of innovation”).

- Two meetings were held with researchers from CERGAS, who collaborate with Fondazione CNAO on health technology assessment (HTA) and cost–benefit analysis. They are expected to contribute to the activities of the Domain OTGs.
- WEB2LEARN reached out to Domain 3, expressing interest in raising public awareness and developing supportive initiatives and promoting patient and public engagement to improve continuous medical education and enhance literacy and involvement.
- Preliminary contacts were initiated by EuroSIG researchers. The project aims to develop a new gantry system, which is a technology of interest for Domain 3. Within the EuroSIG framework—whose ultimate goal is to prepare a commercial proposal to engage potential industrial partners—discussions with clinical experts on the actual clinical benefits of such a gantry should be integrated. This topic could serve as the basis for developing a relevant use case within the Innovative Radiotherapies Domain, directly linked to measurable clinical impact.
- **Domain 4:**
 - ESSO (European Society for Surgical Oncology): (via president Gerhard Beets) for the survey, Oncoinvent (industry);
 - ESTS (European Society of Thoracic Surgery): via Matthieu Faron for the survey.
- **Domain 5:**
 - InspECT: A meeting was held with InspECT to explore potential paths for collaboration.
 - CIRSE: Two meetings were held with the CIRSE Relations Board.
- **Domain 6:**
 - The EBMT
 - The GoCART Coalition
- **Domain 7:**
 - Erasmus Rotterdam (Academia)
 - Janvier labs (Industry (pharma))
 - Crown Bioscience (Industry (pharma))
 - EurOPDX (Academia)



13 SUSTAINABILITY

The development of D10.1 (governance of the NoE) has been a key part of the work undertaken by the NoE to ensure the sustainability of the network. This work has been an important step in ensuring the longevity and efficiency of the NoE past the end of the duration of the joint action.

WP10 has also made an active contribution to WP4, working with them to develop the sustainability strategy. We have collaborated with them to identify key stakeholders for each of the seven domains.

The [M10.1] is part of the Joint Action "JANE-2", GA 101183265, which has received co-funding from the European Union under the EU4Health programme



DOCUMENT INFORMATION

Author(s): Venice Hancock, Jean-Yves Blay

Milestone lead partner: Unicancer (FR) and ZEALCO (DK)

Contributing partner(s): Region Zealand, National and Kapodistrian University of Athens, Hospital Universitario y Politécnico La Fe, CONSELLERIA DE SANIDAD - GENERALITAT VALENCIANA, National Hellenic Research Foundation, Centro Nazionale di Adroterapia Oncologica (CNAO), Oslo University Hospital, Department of Oncology (OUS), Institute of Oncology Ljubljana, Istituto Romagnolo per lo Studio dei Tumori Dino Amadori

Work Package 10

Task number MS10.1

Due delivery date 30/11/2025

Actual delivery date 28/11/2025

Annex version

Revision History

Version no.	Date of issue	Author(s)	Brief description of change
1	15/10/2025	Venice Hancock, Jean-Yves Blay	First Draft
2	21/11/2025	Venice Hancock, Jean-Yves Blay	Second draft: input from domain leaders, grammatical and spelling corrections.